Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivermectin long acting injectable - Medincell

Drug Profile

Ivermectin long acting injectable - Medincell

Alternative Names: mdc-STM; mdc-TTG

Latest Information Update: 10 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedinCell S.A.
  • Developer MedinCell S.A.; Monash University
  • Class Antimalarials; Antineoplastics; Antiparasitics; Antivirals; Macrolides; Skin disorder therapies; Small molecules
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections
  • No development reported Malaria

Most Recent Events

  • 03 Sep 2024 MedinCell plans a phase I clinical trial for Malaria in 2025
  • 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Australia (SC, Injection)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Malaria in France (Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top